Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists: the Cache County study - PubMed (original) (raw)
. 2000 Jun 13;54(11):2066-71.
doi: 10.1212/wnl.54.11.2066.
Affiliations
- PMID: 10851364
- DOI: 10.1212/wnl.54.11.2066
Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists: the Cache County study
J C Anthony et al. Neurology. 2000.
Abstract
Objective: To test the hypothesis that nonsteroidal anti-inflammatory drugs (NSAIDs) and histamine H2 receptor antagonists (H2RAs) are associated with a decreased risk of AD in late life.
Background: Sustained use of non-aspirin NSAIDs has been repeatedly associated with a reduced occurrence of AD. Similar effects with aspirin have been weaker. One prior study showed a strong association between use of H2RAs and reduced AD prevalence.
Methods: In a population study of AD in Cache County, UT, we used a sequenced plan of sampling and case ascertainment to identify 201 cases of AD and 4425 participants with no indication of cognitive impairment. Independently, an interview and medicine chest inventory assessed use of several medicines including aspirin, non-aspirin NSAIDs, H2RAs, and three classes of "control" drugs not thought to be associated with AD. Follow-up questioning probed possible indications for use of these drugs.
Results: Compared with cognitively intact individuals, the AD cases had significantly less reported current use of NSAIDs, aspirin, and H2RAs. Stronger associations appeared when subjects reported use of both NSAIDs and aspirin (no H2RAs), two different NSAIDs (no H2RAs), or two different H2RAs (with neither aspirin nor NSAIDs). There was little or no such association with use of the control medicines. Adjustment for usage indication did not influence these findings, and there was no appreciable variation with number of APOE epsilon4 alleles.
Conclusions: As predicted, use of NSAIDs and aspirin were specifically associated with reduced occurrence of AD. Notably, a previous observation of an inverse association of AD and use of H2RAs was also affirmed. Definitive evidence for a preventive action of these agents will require randomized prevention trials.
Similar articles
- Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County Study.
Zandi PP, Anthony JC, Hayden KM, Mehta K, Mayer L, Breitner JC; Cache County Study Investigators. Zandi PP, et al. Neurology. 2002 Sep 24;59(6):880-6. doi: 10.1212/wnl.59.6.880. Neurology. 2002. PMID: 12297571 - Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs.
Breitner JC, Welsh KA, Helms MJ, Gaskell PC, Gau BA, Roses AD, Pericak-Vance MA, Saunders AM. Breitner JC, et al. Neurobiol Aging. 1995 Jul-Aug;16(4):523-30. doi: 10.1016/0197-4580(95)00049-k. Neurobiol Aging. 1995. PMID: 8544901 - The impact of acid suppression medications and non-steroidal anti-inflammatory drugs on clinical and histologic features in celiac disease.
Jordan R, Shannahan S, Lewis SK, Krishnareddy S, Leffler DA, Green PHR, Lebwohl B. Jordan R, et al. Dig Liver Dis. 2017 Aug;49(8):883-886. doi: 10.1016/j.dld.2017.03.018. Epub 2017 Apr 2. Dig Liver Dis. 2017. PMID: 28462884 Free PMC article. - Anti-inflammatory drugs and risk of Alzheimer's disease: an updated systematic review and meta-analysis.
Wang J, Tan L, Wang HF, Tan CC, Meng XF, Wang C, Tang SW, Yu JT. Wang J, et al. J Alzheimers Dis. 2015;44(2):385-96. doi: 10.3233/JAD-141506. J Alzheimers Dis. 2015. PMID: 25227314 Review. - Pharmacologic management of Alzheimer disease part III: nonsteroidal antiinflammatory drugs--emerging protective evidence?
Flynn BL, Theesen KA. Flynn BL, et al. Ann Pharmacother. 1999 Jul-Aug;33(7-8):840-9. doi: 10.1345/aph.17093. Ann Pharmacother. 1999. PMID: 10466914 Review.
Cited by
- Neuroinflammation, microglia and implications for anti-inflammatory treatment in Alzheimer's disease.
Krause DL, Müller N. Krause DL, et al. Int J Alzheimers Dis. 2010 Jun 14;2010:732806. doi: 10.4061/2010/732806. Int J Alzheimers Dis. 2010. PMID: 20798769 Free PMC article. - Immunological aetiology of major psychiatric disorders: evidence and therapeutic implications.
Sperner-Unterweger B. Sperner-Unterweger B. Drugs. 2005;65(11):1493-520. doi: 10.2165/00003495-200565110-00004. Drugs. 2005. PMID: 16033289 Review. - Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease.
Kitazawa M, Oddo S, Yamasaki TR, Green KN, LaFerla FM. Kitazawa M, et al. J Neurosci. 2005 Sep 28;25(39):8843-53. doi: 10.1523/JNEUROSCI.2868-05.2005. J Neurosci. 2005. PMID: 16192374 Free PMC article. - Gastric acid suppressants and cognitive decline in people with or without cognitive impairment.
Wu CY, Xiong LY, Ouk M, Rabin JS, Herrmann N, Lanctôt KL, Kapral MK, Law M, Cogo-Moreira H, Edwards JD, Swardfager W. Wu CY, et al. Alzheimers Dement (N Y). 2022 Feb 10;8(1):e12243. doi: 10.1002/trc2.12243. eCollection 2022. Alzheimers Dement (N Y). 2022. PMID: 35169610 Free PMC article. - Decreased C-reactive protein levels in Alzheimer disease.
O'Bryant SE, Waring SC, Hobson V, Hall JR, Moore CB, Bottiglieri T, Massman P, Diaz-Arrastia R. O'Bryant SE, et al. J Geriatr Psychiatry Neurol. 2010 Mar;23(1):49-53. doi: 10.1177/0891988709351832. Epub 2009 Nov 20. J Geriatr Psychiatry Neurol. 2010. PMID: 19933496 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous